Consultant physicians working with patients - Royal College of ...

More documents

Recommendations

Info

2 Specialties Rheumatology27 National Institute for Health and Care Excellence.COX-II inhibitors for the treatment of osteoarthritis andrheumatoid arthritis. London: NICE, 2001.http://guidance.nice.org.uk/TA27 [Accessed 4 July2011].28 National Institute for Health and Care Excellence.Etanercept, infliximab and adalimumab for thetreatment of psoriatic arthritis. London: NICE, 2010.http://guidance.nice.org.uk/TA199 [Accessed 4 July2011].29 National Institute for Health and Care Excellence. Theclinical effectiveness and cost effectiveness of etanercept andinfliximab for rheumatoid arthritis and juvenilepoly-articular idiopathic arthritis. London: NICE, 2002.http://guidance.nice.org.uk/TA36 [Accessed 4 July2011].30 National Institute for Health and Care Excellence.Certolizumab pegol for the treatment of rheumatoidarthritis. London: NICE, 2010. http://guidance.nice.org.uk/TA186 [Accessed 4 July 2011].31 National Institute for Health and Care Excellence.Adalimumab, etanercept, infliximab, rituximab andabatacept for the treatment of rheumatoid arthritis afterthe failure of a TNF inhibitor. London: NICE, 2010.http://guidance.nice.org.uk/TA195 [Accessed 4 July2011].32 National Institute for Health and Care Excellence.Tocilizumab for rheumatoid arthritis. London: NICE,2010. http://guidance.nice.org.uk/TA198 [Accessed 4 July2011].33 National Institute for Health and Care Excellence.Febuxostat for the management of hyperuricaemia inpeople with gout. London: NICE, 2008. http://guidance.nice.org.uk/TA164 [Accessed 4 July 2011].34 National Institute for Health and Care Excellence.Alendronate, etidronate, risedronate, raloxifene andstrontium ranelate for the primary prevention ofosteoporotic fragility fractures in postmenopausal women.London: NICE, 2011. http://guidance.nice.org.uk/TA160[Accessed 4 July 2011].35 National Institute for Health and Care Excellence. Theclinical effectiveness and cost effectiveness of technologiesfor the secondary prevention of osteoporotic fractures inpostmenopausal women. London: NICE, 2005.http://guidance.nice.org.uk/TA87 [Accessed 4 July2011].36 British Society for Rheumatology. Guidelines.London:BSR, 2011. www.rheumatology.org.uk/resources/guidelines/default.aspx [Accessed 4 July 2011].37 Ding T, Ledingham J, Luqmani R, et al. BSR and BHPRrheumatoid arthritis guidelines on safety of anti-TNFtherapies. Rheumatology 2010;49:2217–9. www.rheumatology.org.uk/includes/documents/cm docs/2010/r/ra guidelines on safety of antitnf therapiessept 2010.pdf [Accessed 4 July 2011].38 Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPRGuidelines for the management of giant cell arteritis.Rheumatology 2010;49:1594–7. www.rheumatology.org.uk/includes/documents/cm docs/2010/m/2management of giant cell arteritis.pdf [Accessed 4July 2011].39 Deighton C, Hyrich K, Ding T, et al. BSR and BHPRrheumatoid arthritis guidelines on eligibility criteria forthe first biological. Rheumatology 2010;49:1594–7.www.rheumatology.org.uk/includes/documents/cmdocs/2010/r/2 ra guidelines on eligibility criteria forthe first biological therapy.pdf [Accessed 4 July2011].40 British Society for Rheumatology and British HealthProfessionals in Rheumatology. Quick reference guidelinefor monitoring of disease modifying anti-rheumatic drug(DMARD) therapy. London: BSR, BHPR, 2009.www.rheumatology.org.uk/includes/documents/cmdocs/2009/d/dmard grid november 2009.pdf [Accessed4 July 2011].41 Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPRguidelines for the management of polymyalgiarheumatica. Rheumatology 2010;49:186–90. www.rheumatology.org.uk/includes/documents/cm docs/2009/m/management of polymyalgia rheumatica.pdf[Accessed 4 July 2011].42 Luqmani R, Hennel S, Estrach C, et al. British Society forRheumatology and British Health Professionals inRheumatology guideline for the management ofrheumatoid arthritis (after the first 2 years).Rheumatology 2009;48:436–9. www.rheumatology.org.uk/includes/documents/cm docs/2009/m/managementof rheumatoid arthritis after first 2 years.pdf [Accessed4 July 2011].43 Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPRguideline for disease-modifying anti-rheumatic drug(DMARD) therapy in consultation with the BritishAssociation of Dermatologists. Rheumatology2008;47:924–5. www.rheumatology.org.uk/includes/documents/cm docs/2009/d/diseasemodifyingantirheumatic drug dmard therapy.pdf [Accessed 4 July2011].44 Chakravarty K, McDonald H, Pullar T, et al. Appendix toBSR/BHPR guideline for disease-modifyinganti-rheumatic drug (DMARD) therapy. London: BSR,2010. www.rheumatology.org.uk/includes/documents/cm docs/2010/a/appendix to dmard guideline aug2010.pdf [Accessed 3 August 2011].45 LapraikC,WattsR,BaconP,et al. BSR and BHPRguidelines for the management of adults with ANCAassociated vasculitis. Rheumatology 2008;46:1615–6.www.rheumatology.org.uk/includes/documents/cm docs/2009/m/management of adults with ancaassociated vasculitis.pdf [Accessed 4 July2011].C○ Royal College of Physicians 2013 247
Consultant physicians working with patients46 Jordan KM, Cameron JS, Snaith M, et al. British Societyfor Rheumatology and British Health Professionals inRheumatology guideline for the management of gout.Rheumatology 2007;46:1372–4. www.rheumatology.org.uk/includes/documents/cm docs/2009/m/management of gout.pdf [Accessed 4 July 2011].47 Luqmani R, Hennell S, Estrach C, et al. British Society forRheumatology and British Health Professionals inRheumatology guideline for the management ofrheumatoid arthritis (the first 2 years). Rheumatology2006;45:1167–9. www.rheumatology.org.uk/includes/documents/cm docs/2009/m/management ofrheumatoid arthritis first 2 years.pdf [Accessed 4 July2011].48 Coakley G, Mathews C, Field M, et al. BSR & BHPR,BOA, RCGP and BSAC guidelines for management of thehot swollen joint in adults. Rheumatology2006;45:1039–41.www.rheumatology.org.uk/includes/documents/cmdocs/2009/m/management of hot swollen joints inadults.pdf [Accessed 4 July 2011].49 Kyle S, Chandler D, Griffiths CEM, et al. Guideline foranti-TNF-α therapy in psoriatic arthritis. Rheumatology2005;44:390–7. www.rheumatology.org.uk/includes/documents/cm docs/2009/a/antitnf alpha therapyin psoriatic arthritis.pdf [Accessed 4 July 2011].50 Ledingham J, Deighton C. Update on the British Societyfor Rheumatology guidelines for prescribing TNFαblockers in adults with rheumatoid arthritis (update ofprevious guidelines of April 2001). Rheumatology2005;44:157–63. www.rheumatology.org.uk/includes/documents/cm docs/2009/p/prescribing tnf blockersin adults with rheumatoid arthritis.pdf [Accessed 4 July2011].51 Kennedy T, McCabe C, Struthers G, et al. BSR guidelineson standards of care for persons with rheumatoidarthritis. Rheumatology 2005;44:553–6. www.rheumatology.org.uk/includes/documents/cm docs/2009/s/standards of care for persons withrheumatoid arthritis.pdf [Accessed 4 July 2011].52 Keat A, Barkham N, Bhalla A, et al. BSR guideline forprescribing TNFα blockers in adults with ankylosingspondylitis. London: BSR, 2004. www.rheumatology.org.uk/includes/documents/cm docs/2009/p/prescribing tnf alpha blockers in adults withankylosing spondylitis.pdf [Accessed 4 July 2011].53 Arthritis and Musculoskeletal Alliance. Standards of care– project overview. Exeter: ARMA, 2011. www.arma.uk.net/overview.html [Accessed 4 July 2011].54 Arthritis and Musculoskeletal Alliance. Standards of carefor people with back pain. Exeter: ARMA, 2004.www.arma.uk.net/pdfs/bp06.pdf [Accessed 4 July 2011].55 Arthritis and Musculoskeletal Alliance. Standards of carefor people with inflammatory arthritis. Exeter: ARMA,2004. www.arma.uk.net/pdfs/ia06.pdf [Accessed 4 July2011].56 Arthritis and Musculoskeletal Alliance. Standards of carefor people with osteoarthritis. Exeter: ARMA, 2004.www.arma.uk.net/pdfs/oa06.pdf [Accessed 4 July2011].57 Arthritis and Musculoskeletal Alliance. Standards of carefor people with connective tissue diseases. Exeter: ARMA,2007. www.arma.uk.net/pdfs/ctdweb.pdf [Accessed 4 July2011].58 Arthritis and Musculoskeletal Alliance. Standards of carefor people with metabolic bone disease. Exeter: ARMA,2007. www.arma.uk.net/pdfs/mbdweb.pdf [Accessed 4July 2011].59 Arthritis and Musculoskeletal Alliance. Standards of carefor people with regional musculoskeletal pain. Exeter:ARMA, 2007. www.arma.uk.net/pdfs/rmpweb.pdf[Accessed 4 July 2011].60 Arthritis and Musculoskeletal Alliance. Standards of carefor people with musculoskeletal skeletal conditions:overarching principles. Exeter: ARMA, 2004. www.arma.uk.net/pdfs/Overarching%20Principles.pdf [Accessed 4July 2011].61 Arthritis and Musculoskeletal Alliance. Standards of carefor people with musculoskeletal foot health problems.Exeter: ARMA, 2004. www.arma.uk.net/pdfs/musculoskeletalfoothealthproblems.pdf [Accessed 4 July2011].62 Arthritis and Musculoskeletal Alliance. ARMA charter forwork for people affected by musculoskeletal disorders in theUK. Exeter: ARMA, 2010. www.arma.uk.net/pdfs/ARMA%20work%20charter%20FINAL.pdf [Accessed 4July 2011].63 British Society for Rheumatology. London: BSR.www.rheumatology.org.uk/members/action plan.aspx[Accessed 4 July 2011].64 British Society for Rheumatology. The BSR BiologicsRegister. London: BSR. www.rheumatology.org.uk/bsrbiologics register/default.aspx [Accessed 4 July 2011].65 Royal College of Nursing. Rheumatology nursing. Resultof a survey exploring the performance and activity ofrheumatology nurses. London: RCN. www.rcn.org.uk66 Bukhari M, Dixey J, Deighton C. A survey of new tofollow-up ratios in rheumatology outpatientdepartments. Clin Med 2011;11:99–100.67 Baskar S, Obrenovic, Hirsch G, et al. West and EastMidlands region-wide rheumatology case mixsurvey. Rheumatology 2010;49(suppl 1):i24 (PosterOP55).68 Harrison MJ, Deighton C, Symmons DP. An update onUK rheumatology consultant workforce provision: theBSR/ARC Workforce Register 2005–07: assessing theimpact of recent changes in NHS provision.Rheumatology 2008;47:1065–9.248 C○ Royal College of Physicians 2013
Page 1 and 2:
Consultant physiciansworking with p
Page 3 and 4:
The Royal College of PhysiciansThe
Page 5 and 6:
AcknowledgementsWe would like to th
Page 7:
AbbreviationsA&EAACsAMUsARCPCCGsCCS
Page 12 and 13:
1 Physicians in the NHS todaycan be
Page 15 and 16:
Consultant physicians working with
Page 17 and 18:
Page 19 and 20:
Page 22 and 23:
2 The work of the specialties2 The
Page 24 and 25:
2 Specialties Acute internal medici
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32:
Page 35 and 36:
Page 37 and 38:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 54 and 55:
2 Specialties Cardiovascular medici
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
2 Specialties Clinical geneticsClin
Page 68 and 69:
2 Specialties Clinical geneticsPati
Page 70 and 71:
2 Specialties Clinical genetics6 Cl
Page 72:
2 Specialties Clinical geneticswork
Page 75 and 76:
Page 77 and 78:
Page 80 and 81:
2 Specialties Clinical pharmacology
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
2 Specialties DermatologyDermatolog
Page 90 and 91:
2 Specialties Dermatology run monit
Page 92 and 93:
2 Specialties DermatologyDermatolog
Page 94 and 95:
2 Specialties DermatologyTable 1 Ex
Page 96:
2 Specialties Dermatology4 Parkin D
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 106 and 107:
2 Specialties Gastroenterology and
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 134 and 135:
2 Specialties HaematologyHaematolog
Page 136 and 137:
2 Specialties HaematologyTable 2 A
Page 138 and 139:
2 Specialties Haematologythey have
Page 140 and 141:
2 Specialties HaematologyTable 4 Sp
Page 142:
2 Specialties Haematology11 Departm
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 160 and 161:
2 Specialties Medical oncologyMedic
Page 162 and 163:
2 Specialties Medical oncologyaroun
Page 164 and 165:
2 Specialties Medical oncologyset b
Page 166 and 167:
2 Specialties Medical oncologyTable
Page 168 and 169:
2 Specialties Medical ophthalmology
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
2 Specialties Metabolic medicineMet
Page 176 and 177:
2 Specialties Metabolic medicineof
Page 178:
2 Specialties Metabolic medicinemet
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 196 and 197:
2 Specialties Palliative medicinePa
Page 198 and 199:
2 Specialties Palliative medicine-
Page 200 and 201:
2 Specialties Palliative medicineA
Page 202 and 203:
2 Specialties Palliative medicineTa
Page 204: 2 Specialties Palliative medicine24
Page 207 and 208: Consultant physicians working with
Page 212 and 213: 2 Specialties Rehabilitation medici
Page 220 and 221: 2 Specialties Renal medicineRenal m
Page 222 and 223: 2 Specialties Renal medicineLocal a
Page 224 and 225: 2 Specialties Renal medicineInvolve
Page 226 and 227: 2 Specialties Renal medicineAcademi
Page 228 and 229: 2 Specialties Renal medicineTable 1
Page 230: 2 Specialties Renal medicinekidney
Page 253: Consultant physicians working with
Page 270 and 271: 3 Supporting the delivery of high-q
Page 280: 3 Supporting the delivery of high-q
show all

Consultant physicians working with patients - Royal College of ...

Create successful ePaper yourself

Delete template?

Save as template?